We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zoetis' global Companion Animal revenues fell 6% organically, while U.S. Companion Animal declined 11%.
ZTS cut 2026 revenue guidance to $9.12B-$9.32B as July trends showed no market stabilization.
Zoetis is using targeted rebates, promotions and bundles to defend volume and share without broad price cuts.
Zoetis Inc. (ZTS - Free Report) used its second-quarter 2026 earnings call to reset expectations for 2026 as weaker veterinary clinic traffic, pet-owner price sensitivity and heavier competition pressured major Companion Animal franchises.
CEO Kristin Peck said management is not assuming the market becomes easier soon. The response centers on targeted promotions, sharper commercial execution, cost discipline and continued investment in innovation.
ZTS Faces Tougher Companion Animal Conditions
CEO Kristin Peck said pressure intensified in the second quarter, particularly in Dermatology and U.S. parasiticides. Global Companion Animal revenues fell 6% on an organic operational basis, while U.S. Companion Animal declined 11%.
CFO Wetteny Joseph said Key Dermatology revenues fell 16%, with Apoquel facing softer demand and stronger promotional competition. The Simparica franchise was flat globally as international growth offset U.S. weakness.
ZTS’ second-quarter 2026 adjusted earnings of $1.87 per share exceeded the Zacks Consensus Estimate of $1.84. However, revenues of $2.47 billion missed the Zacks Consensus Estimate of $2.49 billion by 0.90%.
CFO Wetteny Joseph revised full-year revenue guidance to $9.12 billion to $9.32 billion, implying an organic operational decline of 3% to 1%. Adjusted diluted earnings are now expected at $6.15 to $6.25.
Adjusted net income is projected at $2.57 billion to $2.62 billion, down 9% to 5% organically. CFO Wetteny Joseph said management incorporated July trends, which had not shown market stabilization.
CFO Wetteny Joseph said the high end assumes contained pricing and competitive pressure, manageable share losses in Dermatology and parasiticides, and continued strength in Livestock and Diagnostics. The low end assumes worsening competition, continued July weakness and slower Livestock uptake.
ZTS Uses Promotions to Defend Share
A Morgan Stanley analyst pressed management on pricing. CEO Kristin Peck said Zoetis is avoiding broad list-price cuts and instead using targeted gross-to-net investments, including rebates, promotions, cross-portfolio bundles and point-of-sale support.
A William Blair analyst asked about the margin implications. CEO Kristin Peck reiterated that these actions are intended to protect volume and share while preserving the longer-term value of the franchises.
CFO Wetteny Joseph later told a Stifel analyst that full-year price realization could range from flat to negative 1%, and potentially negative 2% near the low end of guidance, depending on competitive responses.
Zoetis Leans on Livestock and Diagnostics
CEO Kristin Peck highlighted diversification as an important counterweight. Livestock revenue grew 11% organically, while Companion Animal Diagnostics increased 12%.
CFO Wetteny Joseph said U.S. Livestock rose 23%, helped by cattle demand, supply timing and New World screwworm-related demand. He said some Q2 drivers were transitory and expects second-half U.S. Livestock growth to moderate.
CEO Kristin Peck also pointed to Diagnostics as a growth platform. Zoetis completed the VitalRADS acquisition and continued developing Vetscan OmniMax, with commercial validation still expected by year-end.
ZTS Keeps Innovation and Costs in Focus
CEO Kristin Peck said Zoetis continues to advance a pipeline containing more than 12 potential blockbusters, including opportunities in chronic kidney disease, oncology, cardiology, anxiety and obesity.
The company is also expanding its OA pain portfolio with Lenivia and Portela in Canada and Europe. CEO Kristin Peck said early experience supported broader launches and reinforced management’s confidence in the category.
CFO Wetteny Joseph said adjusted SG&A declined 4% operationally as cost actions took hold, while adjusted R&D rose 4%. Zoetis also repurchased more than $550 million of shares during the quarter.
Zoetis Reshapes Leadership for Execution
CEO Kristin Peck framed leadership changes as part of the push for faster execution. Abhay Nayak was promoted to lead U.S. Commercial Operations, where performance has been under pressure.
Jay Saccaro is joining as executive vice president, CFO and COO, combining finance with oversight of global manufacturing and supply. CEO Kristin Peck said the new structure is intended to improve decision-making and connectivity across operations.
Management’s tone remained cautious on the near-term market but firm on its priorities: defend share, control costs, support innovation and use portfolio diversification to navigate weaker Companion Animal demand.
ZTS Zacks Signals Show Conflicting Factors
ZTS carries a Zacks Rank #4 (Sell) at present. Its Value Score of A, Momentum Score of A and VGM Score of B are favorable Style Scores, while the Growth Score of D is weaker.
Under the Zacks framework, favorable Style Scores are designed to complement top Zacks Rank #1 or 2 (Buy) stocks, while a Zacks Rank #4 indicates an unfavorable estimate-revision backdrop. The Zacks Rank can change as analysts revise estimates following the latest results.
View the Zacks #1 Rank List
Image: Bigstock
ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
Key Takeaways
Zoetis Inc. (ZTS - Free Report) used its second-quarter 2026 earnings call to reset expectations for 2026 as weaker veterinary clinic traffic, pet-owner price sensitivity and heavier competition pressured major Companion Animal franchises.
CEO Kristin Peck said management is not assuming the market becomes easier soon. The response centers on targeted promotions, sharper commercial execution, cost discipline and continued investment in innovation.
ZTS Faces Tougher Companion Animal Conditions
CEO Kristin Peck said pressure intensified in the second quarter, particularly in Dermatology and U.S. parasiticides. Global Companion Animal revenues fell 6% on an organic operational basis, while U.S. Companion Animal declined 11%.
CFO Wetteny Joseph said Key Dermatology revenues fell 16%, with Apoquel facing softer demand and stronger promotional competition. The Simparica franchise was flat globally as international growth offset U.S. weakness.
ZTS’ second-quarter 2026 adjusted earnings of $1.87 per share exceeded the Zacks Consensus Estimate of $1.84. However, revenues of $2.47 billion missed the Zacks Consensus Estimate of $2.49 billion by 0.90%.
Zoetis Inc. Price, Consensus and EPS Surprise
Zoetis Inc. price-consensus-eps-surprise-chart | Zoetis Inc. Quote
Zoetis Cuts Its 2026 Outlook
CFO Wetteny Joseph revised full-year revenue guidance to $9.12 billion to $9.32 billion, implying an organic operational decline of 3% to 1%. Adjusted diluted earnings are now expected at $6.15 to $6.25.
Adjusted net income is projected at $2.57 billion to $2.62 billion, down 9% to 5% organically. CFO Wetteny Joseph said management incorporated July trends, which had not shown market stabilization.
CFO Wetteny Joseph said the high end assumes contained pricing and competitive pressure, manageable share losses in Dermatology and parasiticides, and continued strength in Livestock and Diagnostics. The low end assumes worsening competition, continued July weakness and slower Livestock uptake.
ZTS Uses Promotions to Defend Share
A Morgan Stanley analyst pressed management on pricing. CEO Kristin Peck said Zoetis is avoiding broad list-price cuts and instead using targeted gross-to-net investments, including rebates, promotions, cross-portfolio bundles and point-of-sale support.
A William Blair analyst asked about the margin implications. CEO Kristin Peck reiterated that these actions are intended to protect volume and share while preserving the longer-term value of the franchises.
CFO Wetteny Joseph later told a Stifel analyst that full-year price realization could range from flat to negative 1%, and potentially negative 2% near the low end of guidance, depending on competitive responses.
Zoetis Leans on Livestock and Diagnostics
CEO Kristin Peck highlighted diversification as an important counterweight. Livestock revenue grew 11% organically, while Companion Animal Diagnostics increased 12%.
CFO Wetteny Joseph said U.S. Livestock rose 23%, helped by cattle demand, supply timing and New World screwworm-related demand. He said some Q2 drivers were transitory and expects second-half U.S. Livestock growth to moderate.
CEO Kristin Peck also pointed to Diagnostics as a growth platform. Zoetis completed the VitalRADS acquisition and continued developing Vetscan OmniMax, with commercial validation still expected by year-end.
ZTS Keeps Innovation and Costs in Focus
CEO Kristin Peck said Zoetis continues to advance a pipeline containing more than 12 potential blockbusters, including opportunities in chronic kidney disease, oncology, cardiology, anxiety and obesity.
The company is also expanding its OA pain portfolio with Lenivia and Portela in Canada and Europe. CEO Kristin Peck said early experience supported broader launches and reinforced management’s confidence in the category.
CFO Wetteny Joseph said adjusted SG&A declined 4% operationally as cost actions took hold, while adjusted R&D rose 4%. Zoetis also repurchased more than $550 million of shares during the quarter.
Zoetis Reshapes Leadership for Execution
CEO Kristin Peck framed leadership changes as part of the push for faster execution. Abhay Nayak was promoted to lead U.S. Commercial Operations, where performance has been under pressure.
Jay Saccaro is joining as executive vice president, CFO and COO, combining finance with oversight of global manufacturing and supply. CEO Kristin Peck said the new structure is intended to improve decision-making and connectivity across operations.
Management’s tone remained cautious on the near-term market but firm on its priorities: defend share, control costs, support innovation and use portfolio diversification to navigate weaker Companion Animal demand.
ZTS Zacks Signals Show Conflicting Factors
ZTS carries a Zacks Rank #4 (Sell) at present. Its Value Score of A, Momentum Score of A and VGM Score of B are favorable Style Scores, while the Growth Score of D is weaker.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Under the Zacks framework, favorable Style Scores are designed to complement top Zacks Rank #1 or 2 (Buy) stocks, while a Zacks Rank #4 indicates an unfavorable estimate-revision backdrop. The Zacks Rank can change as analysts revise estimates following the latest results.